These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20020667)

  • 1. PARP inhibition in breast cancer.
    Garber J
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):573-5. PubMed ID: 20020667
    [No Abstract]   [Full Text] [Related]  

  • 2. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y; Calvert H
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibitors: will the new class of drugs match the hype?
    Tuma RS
    J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
    Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh MW; Loman N; Scott C; Friedlander M; Kaufman B; Garber JE; Tutt A; Robson ME
    J Clin Oncol; 2011 Nov; 29(32):4224-6. PubMed ID: 21931031
    [No Abstract]   [Full Text] [Related]  

  • 5. BRCA in breast cancer: from risk assessment to therapeutic prediction.
    Diamond JR; Borges VF; Eckhardt SG; Jimeno A
    Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
    Mercier-Vogel L; Bodmer A; Castiglione M
    Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibition outside of BRCA mutation carriers.
    Isakoff SJ
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):757-8. PubMed ID: 21326153
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
    J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Achilles' heel for breast cancer?
    Caldecott KW; Chalmers A
    Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
    [No Abstract]   [Full Text] [Related]  

  • 10. PARP inhibitors in breast cancer: BRCA and beyond.
    Rios J; Puhalla S
    Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A
    Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
    Stebbing J; Ellis P; Tutt A
    Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
    Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer].
    Hashimoto K; Tamura K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1187-91. PubMed ID: 20647696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
    Jones P; Altamura S; Boueres J; Ferrigno F; Fonsi M; Giomini C; Lamartina S; Monteagudo E; Ontoria JM; Orsale MV; Palumbi MC; Pesci S; Roscilli G; Scarpelli R; Schultz-Fademrecht C; Toniatti C; Rowley M
    J Med Chem; 2009 Nov; 52(22):7170-85. PubMed ID: 19873981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's PARPing up for triple-negative breast cancer?
    Sledge GW
    Clin Breast Cancer; 2009 Aug; 9(3):139. PubMed ID: 19661035
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of oncogenetics in the treatment of breast and ovarian cancer].
    Langmár Z; Németh M
    Orv Hetil; 2011 Jul; 152(30):1214-5. PubMed ID: 21733796
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.